Angiogenesis in bladder cancer - Prognostic marker and target for future therapy

Surgical Oncology

Volumn 11, Issue 1-2, 2002, Pages 85-100

  Streeter, Edward H ^a   Harris, Adrian L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY DEXTRO RIBOSE 1 PHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; HALOFUGINONE; HYALURONIC ACID; HYALURONIDASE; HYDROCARBON NUCLEAR TRANSPORTER PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INITIATION FACTOR 4E; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MEMBRANE RECEPTOR; MESSENGER RNA; MIDKINE; MYC PROTEIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PACLITAXEL; PHOSPHATE; PROTEIN; PROTEIN KINASE C; PROTEIN KINASE C GAMMA; PROTEIN P53; SCATTER FACTOR; SURAMIN; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DOWN REGULATION; DRUG ACTIVITY; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; LYMPHOCYTOPENIA; METASTASIS; NEUROPATHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; THROMBOCYTOPENIA;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; CYCLOHEXANES; DNA-BINDING PROTEINS; DRUG COMBINATIONS; ENDOTHELIAL GROWTH FACTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOKINES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PIPERIDINES; QUINAZOLINES; QUINAZOLINONES; SESQUITERPENES; THYMIDINE PHOSPHORYLASE; TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036276703     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(02)00013-0     Document Type: Article

References (142)

1. A novel mechanism of capillary growth in the rat pulmonary microcirculation
2. Isolation of putative progenitor endothelial cells for angiogenesis
3. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
4. Origins of circulating endothelial cells and endothelial outgrowth from blood
5. Vasculogenic mimicry and tumor angiogenesis
6. Angiogenesis in cancer and other diseases
7. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
8. Organ targeting in vivo using phage display peptide libraries
9. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
10. What is the evidence that tumors are angiogenesis dependent? [editorial]
11. Tumor angiogenesis: Therapeutic implications
12. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder
13. Prognostic significance of angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high-grade stage T1 primary bladder cancer
14. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas
15. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer
16. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis
17. Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder [see comments]
18. Prognostic relevance of micro-vessel density in cancer of the urinary bladder
19. Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells
20. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder
21. Detection of angiogenesis activity in malignant bladder tissue and cells
22. Oxygen(es) and the hypoxia-inducible factor-1
23. 2-dependent degradation domain via the ubiquitin-proteasome pathway
24. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation
25. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension
26. HIF-1 alpha is required for solid tumor formation and embryonic vascularization
27. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
28. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT
29. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines
30. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines
31. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR
32. Hypoxia-inducible expression of tumor-associated carbonic anhydrases
33. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes
34. Vascular endothelial growth factor is a secreted angiogenic mitogen
35. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
36. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium
37. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer
38. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis
39. Determination of cytosolic citrulline and nitrate as indicators of nitric oxide in bladder cancer: Possible association with basic fibroblast growth factor
40. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
41. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
42. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
43. Different angiogenic pathways characterize superficial and invasive bladder cancer
44. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer
45. Expression of vascular endothelial growth factor in primary superficial bladder cancer
46. [Immunohistochemical analysis of expression of angiogenic factors and tumor angiogenesis in superficial bladder cancer]
47. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression
48. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc
49. C-Myc in bladder cancer. Clinical findings and analysis of mechanism
50. PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis
51. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer
52. P53 and p53-regulated genes in bladder cancer
53. The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer
54. Prognostic significance of mutations in the p53 gene in superficial bladder cancer [In Process Citation]
55. Recovery of epidermal growth factor in voided urine of patients with bladder cancer
56. Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy
57. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine
58. Expression of scatter factor in human bladder carcinoma
59. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates [see comments]
60. Thymidine phosphorylase is angiogenic and promotes tumor growth
61. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor
62. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma [see comments]
63. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors
64. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer
65. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers
66. Thymidine phosphorylase activity in human bladder cancer: Difference between superficial and invasive cancer
67. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma
68. Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder
69. Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion
70. Presence of heparin binding growth factor in mouse bladder tumors and urine from mice with bladder cancer
71. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer
72. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients
73. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers [see comments]
74. Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: Correlation with local relapses
75. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer
76. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules
77. Involvement of heparanase in tumor metastasis and angiogenesis
78. Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line
79. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
80. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
81. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma
82. Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa
83. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis
84. Long-term outcome related to epidermal growth factor receptor status in bladder cancer
85. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma
86. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
87. C-erbB-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value [see comments]
88. Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro
89. Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer
90. Ha-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade
91. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers
92. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis
93. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence
94. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas
95. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer
96. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade
97. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer
98. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours
99. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone
100. Effects of epidermal growth factor on the invasion activity of the bladder cancer cell line
101. Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients
102. Tumor progression and expression of matrix metalloproteinase-2 (MMP-2) mRNA by human urinary bladder cancer cells
103. Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma
104. TPA prognostic value in superficial bladder cancer
105. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer
106. Plasminogen activator (urokinase) causes vascularization of the cornea
107. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression
108. Molecular mediators of angiogenesis in bladder cancer
109. Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models
110. Angiostatin induces and sustains dormancy of human primary tumors in mice
111. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
112. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis
113. Anti-angiogenic agents. Clinical trial design and therapies in development
114. Requirement of vascular integrin alpha v beta 3 for angiogenesis
115. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial
116. Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy
117. Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures
118. Intravesical suramin: A novel agent for the treatment of superficial transitional-cell carcinoma of the bladder
119. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
120. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
121. Halting angiogenesis suppresses carcinoma cell invasion
122. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel
123. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
124. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo
125. Aspirin use and risk of fatal cancer [see comments]
126. Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder
127. Antitumour effects of the angiogenesis inhibitor AGM-1470 on rat urinary bladder tumours induced by N-butyl-N-(4-hydroxybutyl) nitrosamine
128. Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice
129. Immunohistochemical detection of thrombospondin-1 in formalin-fixed, paraffin-embedded tissue
130. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice
131. Inhibitory effect of shark liver oil on cutaneous angiogenesis induced in Balb/c mice by syngeneic sarcoma L-1, human urinary bladder and human kidney tumour cells
132. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis
133. Microvessel density as a prognostic marker for transitional cell carcinoma of the bladder
134. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy
135. Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder?
136. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors
137. Expression of cyclooxygenase-2 in patients with bladder carcinoma
138. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages
139. Cortisone inhibition of tumor angiogenesis measured by a quantitative colorimetric assay in mice
140. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration